Financial Comparison: Agape ATP (NASDAQ:ATPC) vs. QuidelOrtho (NASDAQ:QDEL)

Agape ATP (NASDAQ:ATPC) and QuidelOrtho (NASDAQ:QDEL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Profitability

This table compares Agape ATP and QuidelOrtho’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agape ATP	-125.89%	-8.43%	-7.75%
QuidelOrtho	-45.57%	4.25%	1.56%

Earnings and Valuation

This table compares Agape ATP and QuidelOrtho”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agape ATP	$1.52 million	1.86	-$2.28 million	($1.33)	-2.13
QuidelOrtho	$2.73 billion	0.46	-$1.13 billion	($17.82)	-1.02

Agape ATP has higher earnings, but lower revenue than QuidelOrtho. Agape ATP is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Agape ATP and QuidelOrtho, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agape ATP	1	0	0	0	1.00
QuidelOrtho	2	4	0	0	1.67

QuidelOrtho has a consensus target price of $12.38, suggesting a potential downside of 32.19%. Given QuidelOrtho’s stronger consensus rating and higher possible upside, analysts plainly believe QuidelOrtho is more favorable than Agape ATP.

Volatility and Risk

Agape ATP has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Insider and Institutional Ownership

0.0% of Agape ATP shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 2.0% of Agape ATP shares are owned by company insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

QuidelOrtho beats Agape ATP on 9 of the 13 factors compared between the two stocks.

About Agape ATP

Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S. names. The company's products include ATP1s Survivor Select that contains various essential nutrients required by the human body to maintain normal metabolism; ATP3 Ionized Cal-Mag, a calcium and magnesium minerals supplement; ATP4 Omega Blend, an oil blend that provides a bio-effective balance of essential fatty acids, omega 3, and omega 6; ATP5 BetaMaxx, a natural immune enhancer; AGN-Vege Fruit Fiber, a nutrition-based formulation for intestines and stomach; AGP1-Iron to improve iron deficiency anemia; and YFA-Young Formula, an anti-aging and youthful maintenance supplement. It also provides BEAUNIQUE brand products comprising Mito+, an antioxidant drink for cellular, immune, metabolic, brain, and skin health; and Trim+, which inhibits the activities of carbohydrates digestive enzymes that result in a reduction of the breakdown and absorption of sugars. In addition, the company offers energy masks, including N°1 Med-Hydration, N°2 Med-Whitening, and N°3 Med-Firming, as well as hyaluronic acid serum and mousse facial cleanser under ÉNERGÉTIQUE brand; and soy protein isolate powder, and an antioxidant under Livo5 brand name. Further, it sells health and wellness products; and promotes wellness and wellbeing lifestyle through online editorials, programs, events, and campaigns, as well as provides health therapies. The company was incorporated in 2016 and is headquartered in Kuala Lumpur, Malaysia.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.